1
|
Current report
|
1.5/ F
|
III
|
Topical corticosteroid and tacrolimus 0.1% ointment
|
2.5 mg/kg
3 month
|
Complete clearance
|
2
|
Wetzig T. et al. 2003 17
|
4/ M
|
III
|
topical, low-potency corticosteroids and urea
10% ointment
|
3 mg/kg
18 weeks
|
Complete clearance
|
3
|
Chen et al. 2022 18
|
1.5/ M
|
III
|
low-potency corticosteroids and moisturizing cream
|
3 mg/kg
20 weeks
|
Complete clearance
|
4
|
Craigrow et al. 201819
|
1:3months/NR
2: 1month/ NR
|
CARD14-associated
|
MTX, etanercept, PUVA
|
NR
|
1: Partial
2: Partial
|
5
|
Signa et al. 201920
|
1: 7/ M
2: 7/ M
|
CARD14-associated
|
topical and systemic steroids, etanercept
|
1: 5mg/kg
3 month
2: 5mg/kg
3 month
|
1: Partial
2: Partial
|
6
|
Liang et al. 2020 22
|
7 / M
|
V
|
Corticosteroids, calcineurin inhibitors, MTX, acitretin,
isotretinoin
|
75 mg
2 month
|
Ineffective
|
7
|
Maloney et al. 201726
|
4 / M
|
V
|
Acitretin, MTX
|
50 -125 mg
3 weeks
|
unknown
|
8
|
Lora et al. 201823
|
13 / M
|
III
|
Acitretin, MTX
|
3 mg/kg
4 weeks
|
Ineffective
|
9
|
Bonomo et al. 2018 24
|
7 / F
|
III
|
tacrolimus 0.1% ointment, triamcinolone 0.1% ointment
|
300 mg
5 month
|
Initially, it showed a good response, then CsA had to be discontinued
due to a flare-up of symptoms and concerns about adverse effects
|
10
|
Kim et al. 2015 27
|
17 / M
|
III
|
oral
steroids, phototherapy, acitretin
|
NR
|
Ineffective
|
11
|
Chiramel et al. 202021
|
7 / M
|
CARD14-associated
|
acitretin
|
3-4.5mg/kg
4 month
|
Partial
|